PDS Biotechnology (FRA:EU6) General and Admin. Expense: €10.58 Mil (TTM As of Mar. 2026)


FRA:EU6 PDS Biotechnology Corp FRA:EU6
32 GF Score
Price €0.76
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology General and Admin. Expense?

PDS Biotechnology FRA:EU6 +0.79% 32 General and Admin. Expense is €10.58 Mil as of Mar. 2026. GuruFocus rates FRA:EU6 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. PDS Biotechnology's General and Admin. Expense for the three months ended in Mar. 2026 was €2.65 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €10.58 Mil.

PDS Biotechnology General and Admin. Expense Related Terms

PDS Biotechnology General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for PDS Biotechnology's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology General and Admin. Expense Chart

PDS Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.01 11.56 14.01 13.14 10.69

PDS Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.03 2.96 3.04 1.94 2.65
FRA:EU6
32GF Score
PDS Biotechnology Corp FRA:EU6
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €10.58 Mil mean?
PDS Biotechnology (FRA:EU6) has a General and Admin. Expense of €10.58 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on PDS Biotechnology and its competitors.
Is PDS Biotechnology's General and Admin. Expense too high?
PDS Biotechnology's current General and Admin. Expense is €10.58 Mil. Overall, PDS Biotechnology has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's General and Admin. Expense compare to LTRN and AURX?
PDS Biotechnology's General and Admin. Expense of €10.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on PDS Biotechnology and its competitors. PDS Biotechnology's current General and Admin. Expense is €10.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (FRA:EU6) has a current General and Admin. Expense of €10.58 Mil. The current General and Admin. Expense is €10.58 Mil. PDS Biotechnology's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For PDS Biotechnology (FRA:EU6), the current General and Admin. Expense is €10.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PDS Biotechnology Business Description

Other Exchanges PDSB:USA
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
32GF Score

Get the complete analysis for FRA:EU6

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.76
Price